TABLE IX.B.3.a.
Evidence for the role of oral decongestants in the management of allergic rhinitis
| Study | Year | LOE | Study design | Study groups | Clinical endpoint | Conclusion |
|---|---|---|---|---|---|---|
| Salerno et al.1324 | 2005 | 1a | SR |
|
SBP, DBP, HR | Phenylpropanolamine caused increase in SBP. |
| Salerno et al.1325 | 2005 | 1a | SR |
|
SBP, DBP, HR | Pseudoephedrine caused increase in SBP and HR. |
| Meltzer et al.1323 | 2015 | 1b | RCT |
|
Daily reflective nasal congestion score | Phenylephrine is not better than placebo at relieving nasal congestion. |
| Horak et al.1322 | 2009 | 1b | RCT |
|
Subjective evaluation of nasal congestion | Pseudoephedrine resulted in improvement in nasal congestion. Phenylephrine did not improve nasal congestion. |
| Mucha et al.1321 | 2006 | 1b | RCT |
|
Nasal symptoms, nPIF, QOL | Significant improvement from baseline in all symptoms of AR, nPIF, and QOL with both pseudoephedrine and montelukast. |
| Vernacchio et al.1327 | 2008 | 3b | Non-consecutive cohort | Pseudoephedrine use in pediatric population | Children less than 2 years of age are at the highest risk for toxicity with pseudoephedrine. Safe dosing recommendations are lacking for this age group. | |
| Kernan et al.1326 | 2000 | 3b | Case-control |
|
Association between the use of phenylpropanolamine and the risk of a hemorrhagic stroke. | Phenylpropanolamine is an independent risk factor for hemorrhagic stroke in women. |
| Roberge et al.1328 | 1999 | 4 | Case report | 2-year-old developed psychosis and ataxia after being overmedicated with pseudoephedrine/ dextromethorphan cough preparation. | ||
| Sauder et al.1329 | 1998 | 4 | Case report | 3-year-old with visual hallucinations caused by inappropriately high doses of pseudoephedrine. |
AR = allergic rhinitis; DBP = diastolic blood pressure; HR = heart rate; LOE = level of evidence; nPIF = nasal peak inspiratory flow; QOL = quality of life; RCT = randomized controlled trial; SBP = systolic blood pressure; SR = systematic review.